| Schedule of Segment Reporting Information |
The following table presents selected financial information with respect to the Company's single operating segment for each period presented:
| | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | 2026 | | 2025 | | 2026 | | 2025 | | Collaboration revenue | $ | 898 | | | $ | 1,950 | | | $ | 1,773 | | | $ | 22,508 | | Less: | | | | | | | | | Research and development expenses | | | | | | | | | Direct research and development expenses | | | | | | | | | ENTR-601-44 | 7,213 | | | 4,446 | | | 11,968 | | | 9,180 | | | ENTR-601-45 | 3,029 | | | 4,576 | | | 6,631 | | | 7,435 | | | ENTR-601-50 | 1,727 | | | 2,040 | | | 3,096 | | | 2,732 | | | ENTR-601-51 | 1,260 | | | 2,855 | | | 3,597 | | | 3,681 | | DMD franchise-wide(1) | 3,486 | | | 1,712 | | | 5,225 | | | 1,712 | | | Collaboration services | 301 | | | 527 | | | 535 | | | 1,403 | | Ocular programs | 649 | | | 542 | | | 1,110 | | | 812 | | | Other preclinical and discovery | 406 | | | 682 | | | 1,006 | | | 1,669 | | | Unallocated research and development expenses | | | | | | | | | Personnel related (including stock-based compensation) | 11,795 | | | 13,231 | | | 23,837 | | | 25,987 | | | Facility related and other | 5,503 | | | 7,266 | | | 11,418 | | | 15,340 | | | Total research and development expenses | 35,369 | | | 37,877 | | | 68,423 | | | 69,951 | | | General and administrative expenses | 10,492 | | | 10,922 | | | 20,616 | | | 21,196 | | | Interest and other income | 2,235 | | | 3,924 | | | 4,859 | | | 8,365 | | Provision for (benefit from) income taxes | 35 | | | 178 | | | 73 | | | 178 | | Net (loss) income | $ | (42,763) | | | $ | (43,103) | | | $ | (82,480) | | | $ | (60,452) | |
(1)Represents manufacturing and clinical costs that support across the Company's product candidates targeting DMD.
|